Emerging Challenges or Opportunities? Pharmaceutical Development Considerations for Emerging Markets - Colleen Ruegger, Ph.D. (Novartis)
Emerging Challenges or Opportunities? Pharmaceutical Development Considerations for Emerging Markets
Colleen E. Ruegger, Ph.D.,
Novartis Pharmaceutical Corporation
Today, the global healthcare environment is changing more rapidly than ever before. Our aging population and unhealthy lifestyles are shifting the types of diseases that we need to treat – from infectious diseases to diseases such as diabetes, hypertension and heart failure. These trends are also seen in emerging markets. Emerging markets contain over 60% of the world’s population. As the wealth and the awareness of the importance of healthcare increases in these regions, emerging markets are seen as an interesting option for expansion of market share. However, emerging markets are not the same as the traditional markets in the US, EU and Japan. Patients, regulators and governments need to be approached in new ways. This presentation will review some of the differences that have taken place over the past few decades in the pharmaceutical industry and some of the challenges and opportunities that we face in pharmaceutical development as we expand into these new markets. .
Jan 19th, 2017
Registration: 5:30 PM
Dinner: 6:30 PM
1 Hilton Court, Parsippany, New Jersey, 07054
About the speaker:
Dr. Ruegger received a BS in Pharmacy from Rutgers College of Pharmacy and a Ph.D. in Pharmaceutical Science from Rutgers University. She joined Novartis (legacy Ciba-Geigy) in 1995 as a Senior Scientist and has held positions of increasing responsibility in the Pharmaceutical and Analytical Development section of Technical Research and Development. Dr. Ruegger is currently Global Head of Oral Pharmaceutical Development where she is responsible for chemical and pharmaceutical profiling, pharmaceutical product development, clinical manufacturing and technology transfer. Her interests include Quality by Design, compaction simulation, formulation development of poorly soluble compounds and pediatric drug development. Dr. Ruegger is a member of the American Association of Pharmaceutical Scientists and is a past chair of the Manufacturing, Science and Engineering section of AAPS and is also a member of the Healthcare Businesswomen’s Association (HBA).
Registered and paid online: $50.00
Between-positions, Retirees & Students (WITH ADVANCE REGISTRATION ONLY): $45.00
ADVANCE REGISTRATION WILL END AT 5:00 PM ON TUESDAY JAN 17th; AFTER THAT YOU MUST PAY AT THE DOOR